As a strong advocate for the most defenseless members of society, Kimberly Barone Baden seeks accountability and compensation for victims of corporate misconduct, medical negligence and harmful medical drugs. She manages mass tort pharmaceutical litigation through complex personal injury and economic damages cases.
Kimberly represents children with birth defects allegedly caused by antidepressants, including Zoloft®, Effexor® and Wellbutrin®; the smoking cessation drug, Zyban®; and Zofran® which is used to prevent nausea and vomiting. She previously litigated against GlaxoSmithKline in the Paxil® birth defect litigation. In July 2012, Kimberly was appointed to the Plaintiffs’ Steering Committee in In re Zoloft (sertraline hydrochloride) Products Liability Litigation, MDL 2342; and in November 2015, she was appointed as co-lead counsel of In re Zofran (Ondansetron) Products Liability Litigation, MDL 2657. She also manages the firm’s pharmaceutical litigation regarding Crestor®, Lipitor®, Actos®, Incretin Mimetics, Viagra®, and dialysis products GranuFlo® Powder and NaturaLyte® Liquid acid concentrates.
Kimberly also represents elderly victims of abuse and neglect, litigating cases for nursing home and assisted living facility residents, including advocating against nursing home Admission Arbitration Agreements in Grant v. Magnolia Manor-Greenwood, Inc.
Kimberly frequently speaks on medical litigation topics involving birth defect and nursing home litigation, as well as areas including discovery, trial strategy and mediation.
Prior to joining Motley Rice, Kimberly worked on the Fen-Phen diet drug litigation and served as an attorney with the California District Attorney’s Office in San Diego.